Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 5/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 6/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093218 | 0.99 | CASP3 (0.47) | CASP3STAT3SCN10AHDAC3HDAC4 | |
| SCHEMBL3094450 | 0.93 | CASP3 (0.47) | CASP3STAT3SCN10AGCGRHIF1A | |
| SCHEMBL3097125 | 0.93 | CASP3 (0.49) | CASP3STAT3SCN10AGCGRHIF1A | |
| SCHEMBL3094371 | 0.93 | HDAC3 (0.47) | CASP3STAT3SCN10AHDAC3HDAC4 | |
| SCHEMBL3103024 | 0.92 | CASP3 (0.46) | CASP3STAT3SCN10AHDAC1GCGR | |
| SCHEMBL13362292 | 0.92 | CASP3 (0.46) | CASP3STAT3SCN10AHDAC1GCGR | |
| SCHEMBL13181221 | 0.92 | STAT3 (0.54) | CASP3STAT3GCGRMAPTNPC1 | |
| SCHEMBL3098772 | 0.92 | STAT3 (0.46) | CASP3STAT3SCN10AGCGRHIF1A | |
| SCHEMBL3094729 | 0.92 | HDAC3 (0.47) | CASP3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3102922 | 0.92 | HIF1A (0.49) | CASP3STAT3SCN10AGCGRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279660-A1 | Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors | UNIV EMORY (US) | 2024-08-22 | — | — | US | disclosed |
| US-11976279-B2 | Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors | EMORY UNIVERSITY (US) | 2024-05-07 | — | — | US | disclosed |
| US-20220090079-A1 | Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors | UNIV EMORY (US) | 2022-03-24 | — | — | US | disclosed |
| US-11225660-B2 | Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors | EMORY UNIVERSITY (US) | 2022-01-18 | — | — | US | disclosed |
| US-20190112603-A1 | Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors | UNIV EMORY (US) | 2019-04-18 | — | — | US | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| EP-2569312-B1 | SUBSTITUTED HETEROCYCLYL BENZYL PYRAZOLES, AND USE THEREOF | BAYER IP GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-20130172311-A1 | Substituted heterocyclyl benzyl pyrazoles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-8470811-B2 | Substituted heterocyclylbenzylpyrazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-2569309-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | Bayer Intellectual Property GmbH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2569312-A1 | SUBSTITUTED HETEROCYCLYL BENZYL PYRAZOLES, AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20120028950-A1 | Substituted heterocyclylbenzylpyrazoles and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011141325-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141326-A1 | SUBSTITUTED HETEROCYCLYL BENZYL PYRAZOLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2008141731-A2 | INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE AG (DE) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172311-A1 | Substituted heterocyclyl benzyl pyrazoles, and use thereof | HIF1AN, VHL, HIF1A | CASP3 661/4885STAT3 582/4885SCN10A 4834/4885 |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | FLT4, VEGFA, MKI67 | CASP3 448/4885STAT3 426/4885SCN10A 4778/4885 |
| US-20120028950-A1 | Substituted heterocyclylbenzylpyrazoles and use thereof | HIF1AN, VHL, HIF1A | CASP3 792/4885STAT3 642/4885SCN10A 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.